Marinus Pharmaceuticals Inc

NASDAQ:MRNS   3:59:57 PM EDT
12.36
+0.34 (+2.83%)
Products

Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results In Tuberous Sclerosis Complex And Receives FDA Orphan Drug Designation

Published: 08/17/2021 20:36 GMT
Marinus Pharmaceuticals Inc (MRNS) - Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation.
Marinus Pharmaceuticals - Primary Endpoint Showed Median 16.6% Reduction in 28-day Seizure Frequency Relative to Baseline in Tsc Patients.
Marinus Pharmaceuticals - Secondary Endpoint of 50% Responder Rate at 30.4%, Consistent With Marigold Phase 3 Cdkl5 Deficiency Disorder Trial Results.
Marinus Pharmaceuticals - 25.2% Reduction Was Observed in Focal Seizures (n=19), Most Common Seizure Type in Tsc Patients.
Marinus Pharmaceuticals - Phase 3 Planning for Trusttsc Trial Ongoing With First Patient Expected to Be Enrolled in Q4 2021.
Marinus Pharmaceuticals - U.S. FDA Has Granted Orphan Drug Designation to Ganaxolone in Tsc.
Marinus Pharmaceuticals - Ganaxolone Was Generally Well-tolerated With Somnolence Reported As Most Common Adverse Event, Consistent With Previous Trials.
Marinus Pharmaceuticals - One Treatment-related Serious Adverse Event of Seizure Was Reported in Trial.